KR20180006881A - 비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법 - Google Patents
비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법 Download PDFInfo
- Publication number
- KR20180006881A KR20180006881A KR1020177027320A KR20177027320A KR20180006881A KR 20180006881 A KR20180006881 A KR 20180006881A KR 1020177027320 A KR1020177027320 A KR 1020177027320A KR 20177027320 A KR20177027320 A KR 20177027320A KR 20180006881 A KR20180006881 A KR 20180006881A
- Authority
- KR
- South Korea
- Prior art keywords
- day
- nafld
- dystrophy
- subject
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title claims abstract description 108
- 238000000034 method Methods 0.000 title claims abstract description 69
- 238000011282 treatment Methods 0.000 title claims description 19
- 150000002632 lipids Chemical class 0.000 claims abstract description 37
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 31
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims abstract description 25
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 22
- 206010022489 Insulin Resistance Diseases 0.000 claims abstract description 19
- 230000009885 systemic effect Effects 0.000 claims abstract description 19
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 19
- 206010010356 Congenital anomaly Diseases 0.000 claims abstract description 14
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 11
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229940046009 vitamin E Drugs 0.000 claims abstract description 11
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 11
- 239000011709 vitamin E Substances 0.000 claims abstract description 11
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 10
- 201000001421 hyperglycemia Diseases 0.000 claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims description 56
- 150000003839 salts Chemical class 0.000 claims description 45
- 239000000651 prodrug Substances 0.000 claims description 39
- 229940002612 prodrug Drugs 0.000 claims description 39
- 150000002148 esters Chemical class 0.000 claims description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 14
- 206010016654 Fibrosis Diseases 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 230000007882 cirrhosis Effects 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 5
- 206010019668 Hepatic fibrosis Diseases 0.000 claims description 2
- 125000003473 lipid group Chemical group 0.000 claims 1
- NMRWDFUZLLQSBN-UHFFFAOYSA-N 2,4-dichloro-n-(3,5-dichloro-4-quinolin-3-yloxyphenyl)benzenesulfonamide Chemical compound ClC1=CC(Cl)=CC=C1S(=O)(=O)NC(C=C1Cl)=CC(Cl)=C1OC1=CN=C(C=CC=C2)C2=C1 NMRWDFUZLLQSBN-UHFFFAOYSA-N 0.000 abstract description 37
- 239000000203 mixture Substances 0.000 abstract description 17
- 239000000556 agonist Substances 0.000 abstract 1
- 208000001848 dysentery Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 36
- 229940079593 drug Drugs 0.000 description 33
- 235000019197 fats Nutrition 0.000 description 23
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 239000000523 sample Substances 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 210000000577 adipose tissue Anatomy 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- -1 acetic Chemical class 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 235000019441 ethanol Nutrition 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 238000007449 liver function test Methods 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 229940123464 Thiazolidinedione Drugs 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 239000002502 liposome Substances 0.000 description 7
- 210000002700 urine Anatomy 0.000 description 7
- 208000003929 Familial Partial Lipodystrophy Diseases 0.000 description 6
- 230000002411 adverse Effects 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 230000004761 fibrosis Effects 0.000 description 6
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 6
- 238000012317 liver biopsy Methods 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 238000009781 safety test method Methods 0.000 description 6
- 231100000041 toxicology testing Toxicity 0.000 description 6
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 5
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 5
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 5
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000035935 pregnancy Effects 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 4
- 108010082126 Alanine transaminase Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 208000010706 fatty liver disease Diseases 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 description 3
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 3
- 229960001243 orlistat Drugs 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 3
- 229960001661 ursodiol Drugs 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- 102000011690 Adiponectin Human genes 0.000 description 2
- 108010076365 Adiponectin Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- 101150104494 CAV1 gene Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 2
- 206010013700 Drug hypersensitivity Diseases 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010019663 Hepatic failure Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010020850 Hyperthyroidism Diseases 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 102000004067 Osteocalcin Human genes 0.000 description 2
- 108090000573 Osteocalcin Proteins 0.000 description 2
- 108010016731 PPAR gamma Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108010050808 Procollagen Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 229940127218 antiplatelet drug Drugs 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 239000003124 biologic agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000003284 homeostatic effect Effects 0.000 description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 description 2
- 208000003532 hypothyroidism Diseases 0.000 description 2
- 230000002989 hypothyroidism Effects 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 208000007903 liver failure Diseases 0.000 description 2
- 231100000835 liver failure Toxicity 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 229940127216 oral anticoagulant drug Drugs 0.000 description 2
- 238000007410 oral glucose tolerance test Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000009597 pregnancy test Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 108010034596 procollagen Type III-N-terminal peptide Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000007863 steatosis Effects 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 150000001467 thiazolidinediones Chemical class 0.000 description 2
- 229960004394 topiramate Drugs 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 101150107888 AKT2 gene Proteins 0.000 description 1
- 102000014777 Adipokines Human genes 0.000 description 1
- 108010078606 Adipokines Proteins 0.000 description 1
- 206010001367 Adrenal insufficiency Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 241001134772 Bifidobacterium pseudocatenulatum Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101150073841 Bscl2 gene Proteins 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 238000008789 Direct Bilirubin Methods 0.000 description 1
- 206010072268 Drug-induced liver injury Diseases 0.000 description 1
- 208000034669 Dunnigan type familial partial lipodystrophy Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000020970 Familial partial lipodystrophy, Dunnigan type Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100026535 Fibronectin type III domain-containing protein 5 Human genes 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 102000007563 Galectins Human genes 0.000 description 1
- 108010046569 Galectins Proteins 0.000 description 1
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 101100190607 Homo sapiens AGPAT2 gene Proteins 0.000 description 1
- 101000869049 Homo sapiens Caveolae-associated protein 1 Proteins 0.000 description 1
- 101001129132 Homo sapiens Perilipin-1 Proteins 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102100030703 Interleukin-22 Human genes 0.000 description 1
- 101800001026 Irisin Proteins 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229940084845 Metalloproteinase-1 inhibitor Drugs 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000007944 Nodular Nonsuppurative Panniculitis Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010068786 Overlap syndrome Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033649 Pancreatitis chronic Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102100031261 Perilipin-1 Human genes 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 101710168285 Serpin A12 Proteins 0.000 description 1
- 102100036400 Serpin A12 Human genes 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 206010042458 Suicidal ideation Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000026736 Weber-Christian disease Diseases 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- 208000026589 Wolman disease Diseases 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- 208000004622 abetalipoproteinemia Diseases 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000478 adipokine Substances 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 208000017515 adrenocortical insufficiency Diseases 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 238000007681 bariatric surgery Methods 0.000 description 1
- WWIWLTSSHDKOKO-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1.OS(=O)(=O)C1=CC=CC=C1 WWIWLTSSHDKOKO-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 238000009809 bilateral salpingo-oophorectomy Methods 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 231100000594 drug induced liver disease Toxicity 0.000 description 1
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 1
- 230000001648 edemagenic effect Effects 0.000 description 1
- 238000002565 electrocardiography Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 102000013361 fetuin Human genes 0.000 description 1
- 108060002885 fetuin Proteins 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000021554 flavoured beverage Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 208000007345 glycogen storage disease Diseases 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 108010074109 interleukin-22 Proteins 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical compound [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- LNQCUTNLHUQZLR-OZJWLQQPSA-N iridin Chemical compound OC1=C(OC)C(OC)=CC(C=2C(C3=C(O)C(OC)=C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C=C3OC=2)=O)=C1 LNQCUTNLHUQZLR-OZJWLQQPSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 208000006132 lipodystrophy Diseases 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- XTTZERNUQAFMOF-QMMMGPOBSA-N lorcaserin Chemical compound C[C@H]1CNCCC2=CC=C(Cl)C=C12 XTTZERNUQAFMOF-QMMMGPOBSA-N 0.000 description 1
- 229960005060 lorcaserin Drugs 0.000 description 1
- 235000020845 low-calorie diet Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 208000023463 mandibuloacral dysplasia Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000003818 metabolic dysfunction Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960000668 metreleptin Drugs 0.000 description 1
- 108700008455 metreleptin Proteins 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- ZXERDUOLZKYMJM-ZWECCWDJSA-N obeticholic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)CCC(O)=O)CC[C@H]21 ZXERDUOLZKYMJM-ZWECCWDJSA-N 0.000 description 1
- 229960001601 obeticholic acid Drugs 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical class C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000005163 right hepatic lobe Anatomy 0.000 description 1
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 description 1
- 229960003015 rimonabant Drugs 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 201000006152 substance dependence Diseases 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 238000009810 tubal ligation Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020227016427A KR20220070057A (ko) | 2015-03-09 | 2016-03-07 | 비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562130488P | 2015-03-09 | 2015-03-09 | |
| US62/130,488 | 2015-03-09 | ||
| PCT/US2016/021162 WO2016144862A1 (en) | 2015-03-09 | 2016-03-07 | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227016427A Division KR20220070057A (ko) | 2015-03-09 | 2016-03-07 | 비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20180006881A true KR20180006881A (ko) | 2018-01-19 |
Family
ID=56879272
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020177027320A Ceased KR20180006881A (ko) | 2015-03-09 | 2016-03-07 | 비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법 |
| KR1020227016427A Ceased KR20220070057A (ko) | 2015-03-09 | 2016-03-07 | 비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227016427A Ceased KR20220070057A (ko) | 2015-03-09 | 2016-03-07 | 비알코올성 지방간 질환 및/또는 지방이영양증의 치료 방법 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10555929B2 (enExample) |
| EP (1) | EP3267994A4 (enExample) |
| JP (2) | JP2018507914A (enExample) |
| KR (2) | KR20180006881A (enExample) |
| CN (1) | CN107683135A (enExample) |
| AU (2) | AU2016229982B2 (enExample) |
| BR (1) | BR112017019170A2 (enExample) |
| CA (1) | CA2979033A1 (enExample) |
| EA (1) | EA201791982A1 (enExample) |
| HK (1) | HK1249847A1 (enExample) |
| IL (1) | IL254282A0 (enExample) |
| MA (1) | MA42450A (enExample) |
| MX (2) | MX386778B (enExample) |
| SG (2) | SG10202103552XA (enExample) |
| TW (1) | TWI769976B (enExample) |
| WO (1) | WO2016144862A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011140441A2 (en) | 2010-05-06 | 2011-11-10 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
| EP3712254A1 (en) | 2014-05-28 | 2020-09-23 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into gastric tissues through directed differentiation |
| WO2016061464A1 (en) | 2014-10-17 | 2016-04-21 | Children's Hospital Center, D/B/A Cincinnati Children's Hospital Medical Center | In vivo model of human small intetine using pluripotent stem cells and methods of making and using same |
| WO2016144862A1 (en) * | 2015-03-09 | 2016-09-15 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
| CA3016641A1 (en) | 2016-05-05 | 2017-11-09 | Children's Hospital Medical Center | Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same |
| KR102546194B1 (ko) | 2016-11-04 | 2023-06-21 | 칠드런즈 호스피탈 메디칼 센터 | 간 유사 장기 조성물 및 이를 제조 및 사용하는 방법 |
| KR102807995B1 (ko) | 2016-12-05 | 2025-05-16 | 칠드런즈 호스피탈 메디칼 센터 | 결장 유사장기 및 이를 제조 및 사용하는 방법 |
| KR20200036808A (ko) | 2017-04-03 | 2020-04-07 | 코히러스 바이오사이언시스, 인크. | 진행성 핵상 마비 치료를 위한 PPARγ 작용제 |
| JP7248586B2 (ja) | 2017-04-14 | 2023-03-29 | チルドレンズ ホスピタル メディカル センター | 複数ドナー幹細胞組成物およびそれを作製する方法 |
| GB201710229D0 (en) * | 2017-06-27 | 2017-08-09 | Tdeltas Ltd | Compounds for new use |
| GB201715654D0 (en) | 2017-09-27 | 2017-11-08 | Tdeltas Ltd | Method of treatment |
| WO2019074793A1 (en) | 2017-10-10 | 2019-04-18 | Children's Hospital Medical Center | OESOPHAGIAN TISSUE COMPOSITIONS AND / OR ORGANOIDS AND METHODS OF MAKING SAME |
| WO2019126626A1 (en) | 2017-12-21 | 2019-06-27 | Children's Hospital Medical Center | Digitalized human organoids and methods of using same |
| CA3106634A1 (en) | 2018-07-26 | 2020-01-30 | Children's Hospital Medical Center | Hepato-biliary-pancreatic tissues and methods of making same |
| US12428622B2 (en) | 2018-09-12 | 2025-09-30 | Children's Hospital Medical Center | Organoid compositions for the production of hematopoietic stem cells and derivatives thereof |
| GB2577723A (en) | 2018-10-04 | 2020-04-08 | Tdeltas Ltd | Compounds for new use |
| WO2020142365A1 (en) * | 2018-12-31 | 2020-07-09 | Christos Mantzoros | Compositions and methods to treat non-alcoholic fatty liver diseases (nafld) |
| EP3946336A1 (en) * | 2019-04-02 | 2022-02-09 | Coherus Biosciences, Inc. | Compositions and methods to treat non-alcoholic fatty liver diseases (nafld) |
| US20220175758A1 (en) * | 2019-04-04 | 2022-06-09 | Coherus Biosciences, Inc. | Compositions and methods to treat non-alcoholic fatty liver diseases (nafld) |
| EP3946337A1 (en) * | 2019-04-04 | 2022-02-09 | Coherus Biosciences, Inc. | Compositions and methods to treat non-alcoholic fatty liver diseases (nafld) |
| EP3946335A1 (en) * | 2019-04-04 | 2022-02-09 | Coherus Biosciences, Inc. | Compositions and methods to treat non-alcoholic fatty liver diseases (nafld) |
| US20220288054A1 (en) * | 2019-04-04 | 2022-09-15 | Coherus Biosciences, Inc. | Compositions and methods to treat non-alcoholic fatty liver diseases (nafld) |
| US20240066020A1 (en) * | 2019-10-15 | 2024-02-29 | Coherus Biosciences, Inc. | Compositions and methods to treat non-alcoholic fatty liver diseases (nafld) |
| JP2022104747A (ja) * | 2020-12-29 | 2022-07-11 | 国立研究開発法人国立がん研究センター | 抗ウイルス剤 |
| CN118406749A (zh) * | 2024-02-29 | 2024-07-30 | 安徽医科大学 | Caveolin-1基因在制备预防、治疗或缓解非酒精性脂肪肝病的药物中的应用 |
Family Cites Families (402)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE296075C (enExample) | ||||
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| JPS61100519A (ja) | 1984-10-23 | 1986-05-19 | Shin Etsu Chem Co Ltd | 医薬用硬質カプセル |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| DD296075A5 (de) | 1989-08-07 | 1991-11-21 | Martin-Luther-Universitaet Halle-Wittenberg,De | Verfahren zur herstellung neuer inhibitoren der dipeptidyl peptidase iv |
| US5462928A (en) | 1990-04-14 | 1995-10-31 | New England Medical Center Hospitals, Inc. | Inhibitors of dipeptidyl-aminopeptidase type IV |
| WO1991016339A1 (en) | 1990-04-14 | 1991-10-31 | New England Medical Center Hospitals, Inc. | Inhibitors of dipeptidyl-aminopeptidase type iv |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| DK0610317T3 (da) | 1991-10-22 | 2001-02-19 | New England Medical Center Inc | Inhibitorer af dipeptidyl-aminopeptidase type IV |
| US6825169B1 (en) | 1991-10-22 | 2004-11-30 | Trustees Of Tufts College | Inhibitors of dipeptidyl-aminopeptidase type IV |
| MX9206628A (es) | 1991-11-22 | 1993-05-01 | Boehringer Ingelheim Pharma | Ester de prolinaboronato y metodo para su preparacion. |
| US5431917A (en) | 1992-10-08 | 1995-07-11 | Japan Elanco Company, Ltd. | Hard capsule for pharmaceutical drugs and method for producing the same |
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
| US5543396A (en) | 1994-04-28 | 1996-08-06 | Georgia Tech Research Corp. | Proline phosphonate derivatives |
| US20020006899A1 (en) | 1998-10-06 | 2002-01-17 | Pospisilik Andrew J. | Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals |
| DE122010000020I1 (de) | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
| WO1998018763A1 (en) | 1996-10-25 | 1998-05-07 | Tanabe Seiyaku Co., Ltd. | Tetrahydroisoquinoline derivatives |
| US6011155A (en) | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
| US5736151A (en) | 1996-12-09 | 1998-04-07 | Pharmacia & Upjohn Company | Antibiotic oil suspensions |
| ATE304864T1 (de) | 1997-01-07 | 2005-10-15 | Amylin Pharmaceuticals Inc | Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme |
| KR100870353B1 (ko) | 1997-04-07 | 2008-11-25 | 제넨테크, 인크. | 항-ｖｅｇｆ 항체 |
| US6100234A (en) | 1997-05-07 | 2000-08-08 | Tufts University | Treatment of HIV |
| US6040145A (en) | 1997-05-07 | 2000-03-21 | Tufts University | Potentiation of the immune response |
| WO1999016864A1 (en) | 1997-09-29 | 1999-04-08 | Point Therapeutics, Inc. | Stimulation of hematopoietic cells in vitro |
| EP1043328B1 (en) | 1997-11-18 | 2008-03-19 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Novel physiologically active substance sulphostin, process for producing the same, and use thereof |
| US6200995B1 (en) | 1998-01-29 | 2001-03-13 | Tularik Inc. | PPAR-γ modulators |
| US6583157B2 (en) | 1998-01-29 | 2003-06-24 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
| AU766219B2 (en) | 1998-02-02 | 2003-10-09 | 1149336 Ontario Inc. | Method of regulating glucose metabolism, and reagents related thereto |
| US20020061839A1 (en) | 1998-03-09 | 2002-05-23 | Scharpe Simon Lodewijk | Serine peptidase modulators |
| JP2002513762A (ja) | 1998-05-04 | 2002-05-14 | ポイント セラピューティクス， インコーポレイテッド | 造血刺激 |
| DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
| EP1084129B1 (en) | 1998-06-05 | 2003-01-22 | Point Therapeutics, Inc. | Cyclic boroproline compounds |
| DE19828114A1 (de) | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV |
| DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
| DE19834591A1 (de) | 1998-07-31 | 2000-02-03 | Probiodrug Ges Fuer Arzneim | Verfahren zur Steigerung des Blutglukosespiegels in Säugern |
| WO2000010549A1 (en) | 1998-08-21 | 2000-03-02 | Point Therapeutics, Inc. | Regulation of substrate activity |
| US6242422B1 (en) | 1998-10-22 | 2001-06-05 | Idun Pharmacueticals, Inc. | (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases |
| JP3449253B2 (ja) | 1998-10-29 | 2003-09-22 | シオノギクオリカプス株式会社 | 硬質カプセルの製造方法 |
| PT1137666E (pt) | 1998-12-07 | 2008-06-02 | Sod Conseils Rech Applic | Análogos de glp-1 |
| EP1137628A1 (en) | 1998-12-09 | 2001-10-04 | La Jolla Pharmaceutical Company | Molecular scaffolds acting as templates comprising carbamate linkages |
| CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| JP2000191616A (ja) | 1998-12-24 | 2000-07-11 | Senju Pharmaceut Co Ltd | 新規ジペプチジルアルデヒド誘導体およびそれを含有する医薬 |
| DE122007000001I1 (de) | 1999-01-14 | 2007-06-28 | Amylin Pharmaceuticals Inc | Neue exendin agonist Formulierungen und deren Verabreichung |
| JP3018186B1 (ja) | 1999-03-09 | 2000-03-13 | 大阪大学長 | 抗炎症剤、単球系細胞の増殖抑制剤 |
| GB9906714D0 (en) | 1999-03-23 | 1999-05-19 | Ferring Bv | Compositions for improving fertility |
| GB9906715D0 (en) | 1999-03-23 | 1999-05-19 | Ferring Bv | Compositions for promoting growth |
| US20050272652A1 (en) | 1999-03-29 | 2005-12-08 | Gault Victor A | Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity |
| JP3716901B2 (ja) | 1999-04-14 | 2005-11-16 | シオノギクオリカプス株式会社 | セルロースエーテルフィルム |
| JP4121215B2 (ja) | 1999-05-17 | 2008-07-23 | 財団法人微生物化学研究会 | スルフォスチン類縁体、並びにスルフォスチン及びその類縁体の製造方法 |
| JP2003500360A (ja) | 1999-05-25 | 2003-01-07 | ポイント セラピューティクス， インコーポレイテッド | ボロプロリン化合物類を含む抗癌剤 |
| US6107317A (en) | 1999-06-24 | 2000-08-22 | Novartis Ag | N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| US6110949A (en) | 1999-06-24 | 2000-08-29 | Novartis Ag | N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| US6172081B1 (en) | 1999-06-24 | 2001-01-09 | Novartis Ag | Tetrahydroisoquinoline 3-carboxamide derivatives |
| JP4295458B2 (ja) | 1999-06-30 | 2009-07-15 | アムジェン インコーポレイテッド | Ｐｐａｒ−ガンマ活性調節用化合物 |
| US7041691B1 (en) | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
| US6617340B1 (en) | 1999-07-29 | 2003-09-09 | Novartis Ag | N-(substituted glycyl)-pyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| DE19940130A1 (de) | 1999-08-24 | 2001-03-01 | Probiodrug Ges Fuer Arzneim | Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung |
| PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| WO2001034594A1 (en) | 1999-11-12 | 2001-05-17 | Guilford Pharmaceuticals, Inc. | Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors |
| US20040152745A1 (en) | 1999-11-12 | 2004-08-05 | Guilford Pharmaceuticals, Inc. | Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors |
| GB9928330D0 (en) | 1999-11-30 | 2000-01-26 | Ferring Bv | Novel antidiabetic agents |
| US6380398B2 (en) | 2000-01-04 | 2002-04-30 | Novo Nordisk A/S | Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
| JP2003520226A (ja) | 2000-01-21 | 2003-07-02 | ノバルティス アクチエンゲゼルシャフト | ジペプチジルペプチダーゼ−ｉｖ阻害剤および抗糖尿病薬剤を含む組合せ物 |
| JP2003520849A (ja) | 2000-01-24 | 2003-07-08 | ノボ ノルディスク アクティーゼルスカブ | 酵素ｄｐｐ−ｉｖの阻害剤であるｎ−置換２−シアノピロールおよび−ピロリン |
| US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| US6608038B2 (en) | 2000-03-15 | 2003-08-19 | Novartis Ag | Methods and compositions for treatment of diabetes and related conditions via gene therapy |
| AU2001254763A1 (en) | 2000-03-31 | 2001-10-08 | Prosidion Limited | Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
| GB0010188D0 (en) | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
| GB0010183D0 (en) | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
| KR20020089493A (ko) | 2000-04-28 | 2002-11-29 | 상꾜 가부시키가이샤 | ＰＰＡＲγ모듈레이터 |
| WO2001082916A2 (en) | 2000-05-03 | 2001-11-08 | Tularik Inc. | Combination therapeutic compositions and methods of use |
| TW583185B (en) | 2000-06-13 | 2004-04-11 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same |
| US6432969B1 (en) | 2000-06-13 | 2002-08-13 | Novartis Ag | N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| US7078397B2 (en) | 2000-06-19 | 2006-07-18 | Smithkline Beecham Corporation | Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus |
| GB0014969D0 (en) | 2000-06-19 | 2000-08-09 | Smithkline Beecham Plc | Novel method of treatment |
| BRPI0112115B8 (pt) | 2000-06-28 | 2021-05-25 | Japan Tobacco Inc | compostos moduladores ppar-gamma de quinolinil e benzotiazolil |
| US20030171399A1 (en) | 2000-06-28 | 2003-09-11 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
| WO2002002560A2 (en) | 2000-07-04 | 2002-01-10 | Novo Nordisk A/S | Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv) |
| DK1308439T3 (da) | 2000-08-10 | 2009-01-12 | Mitsubishi Tanabe Pharma Corp | Prolinderivater og anvendelse af disse som lægemidler |
| JP4329290B2 (ja) | 2000-10-06 | 2009-09-09 | 田辺三菱製薬株式会社 | 脂肪族含窒素五員環化合物 |
| JP2004035574A (ja) | 2000-10-06 | 2004-02-05 | Tanabe Seiyaku Co Ltd | 脂肪族含窒素五員環化合物 |
| JP4329291B2 (ja) | 2000-10-06 | 2009-09-09 | 田辺三菱製薬株式会社 | 含窒素五員環化合物 |
| NZ524974A (en) | 2000-10-06 | 2005-10-28 | Tanabe Seiyaku Co | Aliphatic nitrogen-containing 5-membered ring compound |
| AUPR107800A0 (en) | 2000-10-27 | 2000-11-23 | University Of Sydney, The | Peptide and nucleic acid molecule ii |
| TWI243162B (en) | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
| WO2002051836A1 (en) | 2000-12-27 | 2002-07-04 | Kyowa Hakko Kogyo Co., Ltd. | Dipeptidyl peptidase iv inhibitor |
| DE10100053A1 (de) | 2001-01-02 | 2002-08-22 | Keyneurotek Ag I G | Verwendung von Enzyminhibitoren der Dipeptidylpeptidase IV sowie der Aminopeptidase N und pharmazeutischen Zubereitungen daraus zur Prävention und/oder Therapie Ischämie-bedingter akuter und chronischer neurodegenerativer Prozesse und Erkrankungen |
| EP1349576B1 (de) | 2001-01-02 | 2011-11-23 | IMTM GmbH | Kombinierte verwendung von enzyminhibitoren zur therapie und prävention allergischer reaktionen vom typ i nach gell und coombs und zur therapie und prävention dermatologischer erkrankungen mit follikulären und epidermalen hyperkeratosen und einer verstärkten keratinozytenproliferation |
| CA2430967C (en) | 2001-01-16 | 2009-06-23 | Nippon Kayaku Kabushiki Kaisha | Remedies for bone marrow suppression and infectious diseases and white blood cell count elevating agents |
| MXPA03006918A (es) | 2001-02-02 | 2004-05-24 | Takeda Chemical Industries Ltd | Compuestos heterociclicos fusionados. |
| JP4213390B2 (ja) | 2001-02-02 | 2009-01-21 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| HU230384B1 (hu) | 2001-02-24 | 2016-03-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xantinszármazékok, előállításuk és alkalmazásuk gyógyszerként |
| JP2002265439A (ja) | 2001-03-08 | 2002-09-18 | Mitsubishi Pharma Corp | シアノピロリジン誘導体およびその医薬用途 |
| DE60226723D1 (de) | 2001-03-27 | 2008-07-03 | Merck & Co Inc | Dipeptidylpeptidase-hemmer für die behandlung oder prävention von diabetes |
| FR2822826B1 (fr) | 2001-03-28 | 2003-05-09 | Servier Lab | Nouveaux derives sulfonyles d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US6890905B2 (en) | 2001-04-02 | 2005-05-10 | Prosidion Limited | Methods for improving islet signaling in diabetes mellitus and for its prevention |
| GB0109146D0 (en) | 2001-04-11 | 2001-05-30 | Ferring Bv | Treatment of type 2 diabetes |
| US6573287B2 (en) | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
| FR2824825B1 (fr) | 2001-05-15 | 2005-05-06 | Servier Lab | Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US20030060494A1 (en) | 2001-05-18 | 2003-03-27 | Nobuyuki Yasuda | Pharmaceutical use of N-carbamoylazole derivatives |
| WO2003000180A2 (en) | 2001-06-20 | 2003-01-03 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| US7253172B2 (en) | 2001-06-20 | 2007-08-07 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| GB0115517D0 (en) | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
| ATE370943T1 (de) | 2001-06-27 | 2007-09-15 | Smithkline Beecham Corp | Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren |
| US20030130199A1 (en) | 2001-06-27 | 2003-07-10 | Von Hoersten Stephan | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents |
| CN1990468A (zh) | 2001-06-27 | 2007-07-04 | 史密丝克莱恩比彻姆公司 | 作为二肽酶抑制剂的氟代吡咯烷 |
| US7368421B2 (en) | 2001-06-27 | 2008-05-06 | Probiodrug Ag | Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis |
| JP4300108B2 (ja) | 2001-06-27 | 2009-07-22 | スミスクライン ビーチャム コーポレーション | ジペプチジルペプチダーゼ阻害剤としてのピロリジン類 |
| EP1399471B1 (en) | 2001-06-27 | 2008-01-30 | Probiodrug AG | Use of dipeptidyl peptidase iv inhibitors as therapeutics for neurological disorders |
| DE10154689A1 (de) | 2001-11-09 | 2003-05-22 | Probiodrug Ag | Substituierte Aminoketonverbindungen |
| CA2419888A1 (en) | 2001-06-27 | 2003-01-09 | Probiodrug Ag | Peptide structures useful for competitive modulation of dipeptidyl peptidase iv catalysis |
| EP1404675B1 (en) | 2001-07-03 | 2008-03-12 | Novo Nordisk A/S | Dpp-iv-inhibiting purine derivatives for the treatment of diabetes |
| US6869947B2 (en) | 2001-07-03 | 2005-03-22 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
| UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
| TWI279052B (en) | 2001-08-31 | 2007-04-11 | Semiconductor Energy Lab | Laser irradiation method, laser irradiation apparatus, and method of manufacturing a semiconductor device |
| US6844316B2 (en) | 2001-09-06 | 2005-01-18 | Probiodrug Ag | Inhibitors of dipeptidyl peptidase I |
| DE10143840A1 (de) | 2001-09-06 | 2003-03-27 | Probiodrug Ag | Neue Inhibitoren der Dipeptidylpeptidase I |
| WO2003024942A1 (en) | 2001-09-14 | 2003-03-27 | Mitsubishi Pharma Corporation | Thiazolidine derivative and medicinal use thereof |
| EP1463727A2 (en) | 2001-09-19 | 2004-10-06 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme dpp-iv |
| GB0125446D0 (en) | 2001-10-23 | 2001-12-12 | Ferring Bv | Novel anti-diabetic agents |
| GB0125445D0 (en) | 2001-10-23 | 2001-12-12 | Ferring Bv | Protease Inhibitors |
| US6861440B2 (en) | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
| JP2005507261A (ja) | 2001-10-31 | 2005-03-17 | ノバルティス アクチエンゲゼルシャフト | Ｔｃｆ１遺伝子における多型に基づく糖尿病および関連状態の治療方法 |
| US20030125304A1 (en) | 2001-11-09 | 2003-07-03 | Hans-Ulrich Demuth | Substituted amino ketone compounds |
| US7236683B2 (en) | 2001-11-15 | 2007-06-26 | Macrovision Corporation | Method and apparatus for providing or enhancing copy protection by adding selected negative-going and positive-going pulses in a video signal HBI |
| JP4771661B2 (ja) | 2001-11-26 | 2011-09-14 | トラスティーズ オブ タフツ カレッジ | Ｐｏｓｔ−プロリン開裂酵素の擬ペプチド性阻害剤 |
| AU2002360453C1 (en) | 2001-11-26 | 2009-06-18 | The Brigham And Women's Hospital, Inc. | Methods for treating autoimmune disorders, and reagents related thereto |
| AU2002360732A1 (en) | 2001-12-26 | 2003-07-24 | Guilford Pharmaceuticals | Change inhibitors of dipeptidyl peptidase iv |
| US6727261B2 (en) | 2001-12-27 | 2004-04-27 | Hoffman-La Roche Inc. | Pyrido[2,1-A]Isoquinoline derivatives |
| US6725848B2 (en) | 2002-01-18 | 2004-04-27 | Detroit Diesel Corporation | Method of controlling exhaust gas recirculation system based upon humidity |
| WO2003072528A2 (en) | 2002-02-08 | 2003-09-04 | Idun Pharmaceuticals, Inc. | (substituted)acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases |
| WO2003068748A1 (en) | 2002-02-13 | 2003-08-21 | F. Hoffmann-La Roche Ag | Novel pyridine- and quinoline-derivatives |
| BR0307665A (pt) | 2002-02-13 | 2005-01-04 | Hoffmann La Roche | Compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para o tratamento e/ou profilaxia de enfermidades associadas com dpp iv e utilização dos compostos |
| US6906074B2 (en) | 2002-02-22 | 2005-06-14 | Nippon Zoki Pharmaceutical Co., Ltd. | 2-phenylpiperazine derivatives |
| EP1338595B1 (en) | 2002-02-25 | 2006-05-03 | Eisai Co., Ltd. | Xanthine derivatives as DPP-IV inhibitors |
| JP2004043429A (ja) | 2002-02-25 | 2004-02-12 | Eisai Co Ltd | 新規キサンチン誘導体およびｄｐｐｉｖ阻害剤 |
| ATE349435T1 (de) | 2002-02-28 | 2007-01-15 | Prosidion Ltd | Dpiv-inhibitoren auf glutaminbasis |
| HUP0200849A2 (hu) | 2002-03-06 | 2004-08-30 | Sanofi-Synthelabo | N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra |
| CA2479898A1 (en) | 2002-03-25 | 2003-10-02 | Masatoshi Abe | Novel .alpha.-amino-n-(diaminophosphinyl)lactam derivatives |
| AU2003225916A1 (en) | 2002-03-25 | 2003-10-13 | Merck & Co., Inc. | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| JP4329382B2 (ja) | 2002-04-04 | 2009-09-09 | 田辺三菱製薬株式会社 | 医薬組成物 |
| JP4329381B2 (ja) | 2002-04-04 | 2009-09-09 | 田辺三菱製薬株式会社 | 医薬組成物 |
| US20040106802A1 (en) | 2002-04-08 | 2004-06-03 | Torrent Pharmaceuticals Ltd. | Novel compounds and therapeutic uses thereof |
| WO2003084940A1 (en) | 2002-04-08 | 2003-10-16 | Alangudi Sankaranarayanan | Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors |
| JP2003300977A (ja) | 2002-04-10 | 2003-10-21 | Sumitomo Pharmaceut Co Ltd | キサンチン誘導体 |
| AU2003235913A1 (en) | 2002-05-09 | 2003-11-11 | Taisho Pharmaceutical Co., Ltd. | Cyanopyrrolidine derivatives |
| JP2004026820A (ja) | 2002-05-09 | 2004-01-29 | Taisho Pharmaceut Co Ltd | ジペプチジルペプチダーゼｉｖ阻害剤 |
| JP2003327532A (ja) | 2002-05-10 | 2003-11-19 | Takeda Chem Ind Ltd | ペプチダーゼ阻害剤 |
| GB0212412D0 (en) | 2002-05-29 | 2002-07-10 | Novartis Ag | Combination of organic compounds |
| CN100402026C (zh) | 2002-06-03 | 2008-07-16 | 诺瓦提斯公司 | 取代的氰基吡咯烷和含有它们的组合制剂用于治疗高脂血症和相关疾病的用途 |
| EP1513808A2 (en) | 2002-06-04 | 2005-03-16 | Pfizer Products Inc. | Fluorinated cyclic amides as dipeptidyl peptidase iv inhibitors |
| US6710040B1 (en) | 2002-06-04 | 2004-03-23 | Pfizer Inc. | Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors |
| AU2003233010A1 (en) | 2002-06-04 | 2003-12-19 | Pfizer Products Inc. | Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof |
| TWI273104B (en) | 2002-06-06 | 2007-02-11 | Eisai Co Ltd | Novel fused imidazole derivative |
| HUP0202001A2 (hu) | 2002-06-14 | 2005-08-29 | Sanofi-Aventis | DDP-IV gátló hatású azabiciklooktán- és nonánszármazékok |
| JP2004026678A (ja) | 2002-06-24 | 2004-01-29 | Microbial Chem Res Found | ２型糖尿病治療剤 |
| JP2006507352A (ja) | 2002-07-09 | 2006-03-02 | ポイント セラピューティクス， インコーポレイテッド | イソロイシンのボロプロリン化合物に関する方法および組成物 |
| WO2004007446A1 (ja) | 2002-07-10 | 2004-01-22 | Yamanouchi Pharmaceutical Co., Ltd. | 新規なアゼチジン誘導体又はその塩 |
| WO2004007468A1 (en) | 2002-07-15 | 2004-01-22 | Merck & Co., Inc. | Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes |
| TW200401635A (en) | 2002-07-23 | 2004-02-01 | Yamanouchi Pharma Co Ltd | 2-Cyano-4-fluoropyrrolidine derivative or salt thereof |
| EP1525306A1 (en) | 2002-07-29 | 2005-04-27 | Tanabe Seiyaku Co., Ltd. | Three-dimensional structure of dipeptidyl peptidase iv |
| JP4542757B2 (ja) | 2002-08-08 | 2010-09-15 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| ATE401311T1 (de) | 2002-08-08 | 2008-08-15 | Takeda Pharmaceutical | Kondensierte heterozyklische verbindungen als petidase inhibitoren |
| DE10238243A1 (de) | 2002-08-21 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| HRP20050157B1 (en) | 2002-08-21 | 2013-01-31 | Boehringer Ingelheim Pharma | 8-[3-amino-piperidin-1-yl]-xanthines,the production thereof and the use of the same as medicaments |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| DE10238477A1 (de) | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| DE10238470A1 (de) | 2002-08-22 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| JPWO2004019352A1 (ja) | 2002-08-26 | 2005-12-15 | 松下電器産業株式会社 | マルチフェーズ用磁性素子とその製造方法 |
| CA2496623C (en) | 2002-08-29 | 2008-02-12 | Taisho Pharmaceutical Co., Ltd. | Benzenesulfonate salts of 4-fluoro-2-cyanopyrrolidine derivatives |
| US8895541B2 (en) | 2002-09-04 | 2014-11-25 | James A. Carnazza | Methods for inhibiting the development of huntington's disease |
| EP1537880A4 (en) | 2002-09-11 | 2009-07-01 | Takeda Pharmaceutical | Sustained release preparation |
| US20040121964A1 (en) | 2002-09-19 | 2004-06-24 | Madar David J. | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
| US7262207B2 (en) | 2002-09-19 | 2007-08-28 | Abbott Laboratories | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
| US7238724B2 (en) | 2002-09-19 | 2007-07-03 | Abbott Laboratories | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
| CA2499586A1 (en) | 2002-10-07 | 2004-04-22 | Merck & Co., Inc. | Antidiabetic beta-amino heterocyclic dipeptidyl peptidase inhibitors |
| AU2003269850A1 (en) | 2002-10-08 | 2004-05-04 | Novo Nordisk A/S | Hemisuccinate salts of heterocyclic dpp-iv inhibitors |
| MXPA05004063A (es) | 2002-10-18 | 2005-06-08 | Merck & Co Inc | Inhibidores de la beta-amino heterociclico dipeptidil peptidasa para el tratamiento o prevencion de diabetes. |
| AU2003282983A1 (en) | 2002-10-23 | 2004-05-13 | Bristol-Myers Squibb Company | Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods |
| WO2004041795A1 (en) | 2002-10-30 | 2004-05-21 | Guilford Pharmaceuticals Inc. | Novel inhibitors of dipeptidyl peptidase iv |
| WO2004048379A1 (ja) | 2002-11-01 | 2004-06-10 | Sumitomo Pharmaceuticals Co., Ltd. | キサンチン化合物 |
| MXPA05004890A (es) | 2002-11-07 | 2005-07-22 | Merck & Co Inc | Derivados de fenilalanina como inhibidores de dipeptidilpeptidasa para el tratamiento o prevencion de diabetes. |
| DE10251927A1 (de) | 2002-11-08 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| US7482337B2 (en) | 2002-11-08 | 2009-01-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
| JP2006508975A (ja) | 2002-11-18 | 2006-03-16 | ファイザー・プロダクツ・インク | ジペプチジルペプチダーゼｉｖを阻害するフッ素化環状アミド |
| DE10254304A1 (de) | 2002-11-21 | 2004-06-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| US7109192B2 (en) | 2002-12-03 | 2006-09-19 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions |
| UY28103A1 (es) | 2002-12-03 | 2004-06-30 | Boehringer Ingelheim Pharma | Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos |
| DE10256264A1 (de) | 2002-12-03 | 2004-06-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Imidazo-pyridinone und Imidazo-pyridazinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
| AU2003297564A1 (en) | 2002-12-04 | 2004-06-23 | Merck & Co., Inc. | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| US7420079B2 (en) | 2002-12-09 | 2008-09-02 | Bristol-Myers Squibb Company | Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof |
| DE60322944D1 (de) | 2002-12-10 | 2008-09-25 | Novartis Ag | Kombinationen von einem dpp-iv inhibitor und einem ppar- alpha agonist |
| WO2004058266A1 (en) | 2002-12-20 | 2004-07-15 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| WO2004064778A2 (en) | 2003-01-17 | 2004-08-05 | Merck & Co. Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| JP2004244412A (ja) | 2003-01-20 | 2004-09-02 | Kotobuki Seiyaku Kk | ４位に置換基を有する２−シアノピロリジン誘導体及びその製造方法並びにそれを含有する薬剤 |
| JP4345313B2 (ja) | 2003-01-24 | 2009-10-14 | 株式会社日立製作所 | ポリシーに基づいたストレージシステムの運用管理方法 |
| WO2004069162A2 (en) | 2003-01-31 | 2004-08-19 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| DK1595866T3 (en) | 2003-01-31 | 2016-08-22 | Sanwa Kagaku Kenkyusho Co | Cyanopyrrolidines suitable for the treatment of inter alia metabolism syndrome |
| WO2004071454A2 (en) | 2003-02-13 | 2004-08-26 | Guilford Pharmaceuticals Inc. | Substituted azetidine compounds as inhibitors of dipeptidyl peptidase iv |
| AU2003207881A1 (en) | 2003-02-28 | 2004-09-17 | Aic | Dipeptidyl peptidase inhibitors |
| WO2004076434A1 (en) | 2003-02-28 | 2004-09-10 | Aic | Dipeptidyl peptidase inhibitors |
| AR043515A1 (es) | 2003-03-19 | 2005-08-03 | Merck & Co Inc | Procedimiento para preparar derivados quirales beta aminoacidos mediante hidrogenacion asimetrica |
| WO2004085661A2 (en) | 2003-03-24 | 2004-10-07 | Merck & Co., Inc | Process to chiral beta-amino acid derivatives |
| KR20050122220A (ko) | 2003-03-25 | 2005-12-28 | 다케다 샌디에고, 인코포레이티드 | 디펩티딜 펩티다제 억제제 |
| WO2004087650A2 (en) | 2003-03-27 | 2004-10-14 | Merck & Co. Inc. | Process and intermediates for the preparation of beta-amino acid amide dipeptidyl peptidase-iv inhibitors |
| WO2004092128A1 (en) | 2003-04-10 | 2004-10-28 | Smithkline Beecham Corporation | Anhydrous crystalline forms of (2s, 4s)-1-{(2r)-2-amino-3-‘4-methoxybenzyl)sulfonyl!-3-methylbutanoyl}-4-fluoropyrrolindine-2-carbonitrile |
| JPWO2004096806A1 (ja) | 2003-04-30 | 2006-07-13 | 大日本住友製薬株式会社 | 縮合イミダゾール誘導体 |
| EP1622870A2 (en) | 2003-05-05 | 2006-02-08 | Prosidion Ltd. | Glutaminyl based dp iv-inhibitors |
| US20040224995A1 (en) | 2003-05-09 | 2004-11-11 | University Of North Texas Health Science Center At Fort Worth | Neuroprotective effects of PPARy agonists against cellular oxidative insults |
| US7560455B2 (en) | 2003-05-14 | 2009-07-14 | Merck & Co., Inc. | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| EP1625122A1 (en) | 2003-05-14 | 2006-02-15 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| JPWO2004101514A1 (ja) | 2003-05-15 | 2006-07-13 | 大正製薬株式会社 | シアノフルオロピロリジン誘導体 |
| EP1631679A2 (en) | 2003-05-21 | 2006-03-08 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase 7 (dpp7) |
| EP1631680A2 (en) | 2003-05-21 | 2006-03-08 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4) |
| AU2003902828A0 (en) | 2003-06-05 | 2003-06-26 | Fujisawa Pharmaceutical Co., Ltd. | Dpp-iv inhibitor |
| AU2004247068A1 (en) | 2003-06-06 | 2004-12-23 | Merck & Co., Inc. | Fused indoles as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| EP1635832A2 (en) | 2003-06-06 | 2006-03-22 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes |
| AU2003902946A0 (en) | 2003-06-12 | 2003-06-26 | Fujisawa Pharmaceutical Co., Ltd. | Dpp-iv inhibitor |
| EP1638950A4 (en) | 2003-06-17 | 2010-06-30 | Merck Sharp & Dohme | CYCLOHEXYLGLYCIN DERIVATIVES AS DIPEPTIDYLPEPTIDASEINHIBITORS FOR THE TREATMENT OF BZW. PREVENTION OF DIABETES |
| US7566707B2 (en) | 2003-06-18 | 2009-07-28 | Boehringer Ingelheim International Gmbh | Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions |
| DE10327439A1 (de) | 2003-06-18 | 2005-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| HRP20110018T1 (hr) | 2003-06-20 | 2011-02-28 | F. Hoffmann - La Roche Ag | Derivati pirido(2,1-a)-izokinolina kao inhibitori dpp-iv |
| ES2327740T3 (es) | 2003-06-20 | 2009-11-03 | F. Hoffmann-La Roche Ag | Hexahidropiridoisoquinolinas como inhibidoras de la dpp-iv. |
| JO2625B1 (en) | 2003-06-24 | 2011-11-01 | ميرك شارب اند دوم كوربوريشن | Phosphoric acid salts of dipeptidyl betidase inhibitor 4 |
| JP2005023038A (ja) | 2003-07-04 | 2005-01-27 | Taisho Pharmaceut Co Ltd | 慢性腎疾患治療薬 |
| US7462641B2 (en) | 2003-07-21 | 2008-12-09 | Smithkline Beecham Corporation | (2S,4S)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-L-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof |
| DE10333935A1 (de) | 2003-07-25 | 2005-02-24 | Aventis Pharma Deutschland Gmbh | Neue bicyclische Cyanoheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US7094800B2 (en) | 2003-07-25 | 2006-08-22 | Sanofi-Aventis Deutschland Gmbh | Cyanopyrrolidides, process for their preparation and their use as medicaments |
| PE20050249A1 (es) | 2003-07-25 | 2005-06-01 | Aventis Pharma Gmbh | Nuevas cianopirrolididas y procedimiento para su preparacion como medicamentos |
| US7008957B2 (en) | 2003-07-25 | 2006-03-07 | Sanofi-Aventis Deutschland Gmbh | Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments |
| WO2005011581A2 (en) | 2003-07-31 | 2005-02-10 | Merck & Co., Inc. | Hexahydrodiazepinones as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| US20050065183A1 (en) | 2003-07-31 | 2005-03-24 | Indranil Nandi | Fexofenadine composition and process for preparing |
| US6995183B2 (en) | 2003-08-01 | 2006-02-07 | Bristol Myers Squibb Company | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods |
| DE10337074A1 (de) | 2003-08-12 | 2005-03-17 | Keyneurotek Ag | Verwendung der Inhibitoren von Enzymen mit Aktivitäten der Aminopeptidase N und/oder der Dipeptidylpeptidase IV und pharmazeutischen Zubereitungen daraus zur Therapie und Prävention von chronischen neurodegenerativen Erkrankungen |
| US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| US7579357B2 (en) | 2003-08-13 | 2009-08-25 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| WO2005019168A2 (en) | 2003-08-20 | 2005-03-03 | Pfizer Products Inc. | Fluorinated lysine derivatives as dipeptidyl peptidase iv inhibitors |
| HU227684B1 (en) | 2003-08-29 | 2011-11-28 | Sanofi Aventis | Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors |
| US20070082908A1 (en) | 2003-08-29 | 2007-04-12 | Dainippon Sumitomo Pharma Co., Ltd. | Bicycle pyrazole derivative |
| US20060287528A1 (en) | 2003-09-02 | 2006-12-21 | Wenslow Robert M | Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor |
| WO2005023762A1 (en) | 2003-09-04 | 2005-03-17 | Abbott Laboratories | Pyrrolidine-2-carbonitrile derivatives and their use as inhibitors of dipeptidyl peptidase-iv (dpp-iv) |
| US7205409B2 (en) | 2003-09-04 | 2007-04-17 | Abbott Laboratories | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
| WO2005030751A2 (en) | 2003-09-08 | 2005-04-07 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| WO2005026148A1 (en) | 2003-09-08 | 2005-03-24 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| TW200530157A (en) | 2003-09-09 | 2005-09-16 | Japan Tobacco Inc | Dipeptidyl peptidase iv inhibitor |
| GB0321100D0 (en) | 2003-09-09 | 2003-10-08 | Celltech R&D Ltd | Biological products |
| WO2005030127A2 (en) | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor |
| CA2540741A1 (en) | 2003-10-03 | 2005-04-14 | Takeda Pharmaceutical Company Limited | Agent for treating diabetes |
| US7223761B2 (en) | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| WO2005033099A2 (en) | 2003-10-03 | 2005-04-14 | Glenmark Pharmaceuticals Ltd. | Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof |
| DE10348044A1 (de) | 2003-10-15 | 2005-05-19 | Imtm Gmbh | Duale Alanyl-Aminopeptidase- und Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| DE10348022A1 (de) | 2003-10-15 | 2005-05-25 | Imtm Gmbh | Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| GB0324236D0 (en) | 2003-10-16 | 2003-11-19 | Astrazeneca Ab | Chemical compounds |
| TW200519105A (en) | 2003-10-20 | 2005-06-16 | Lg Life Science Ltd | Novel inhibitors of DPP-IV, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent |
| WO2005042003A1 (en) | 2003-10-24 | 2005-05-12 | Merck & Co., Inc. | Enhancement of growth hormone levels with a dipeptidyl peptidase iv inhibitor and a growth hormone secretagogue |
| CA2540225C (en) | 2003-10-31 | 2012-03-06 | Takeda Pharmaceutical Company Limited | Solid preparation of pioglitazone, glimepiride and a polyoxyethylene sorbitan fatty acid ester |
| TW200528440A (en) | 2003-10-31 | 2005-09-01 | Fujisawa Pharmaceutical Co | 2-cyanopyrrolidinecarboxamide compound |
| PE20050444A1 (es) | 2003-10-31 | 2005-08-09 | Takeda Pharmaceutical | Compuestos de piridina como inhibidores de la peptidasa |
| JP2007510651A (ja) | 2003-11-04 | 2007-04-26 | メルク エンド カムパニー インコーポレーテッド | 糖尿病の治療又は予防のためのジペプチジルペプチダーゼ−ｉｖ阻害剤としての縮合フェニルアラニン誘導体 |
| DK1689757T3 (en) | 2003-11-12 | 2014-12-08 | Sino Med Internat Alliance Inc | HETEROCYCLIC DRY ACID COMPOUNDS |
| US7317109B2 (en) | 2003-11-12 | 2008-01-08 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| US7767828B2 (en) | 2003-11-12 | 2010-08-03 | Phenomix Corporation | Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| US20070149451A1 (en) | 2003-11-17 | 2007-06-28 | Holmes David G | Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent |
| KR20170104639A (ko) | 2003-11-17 | 2017-09-15 | 노파르티스 아게 | 디펩티딜 펩티다제 ⅳ 억제제의 용도 |
| US20070105890A1 (en) | 2003-11-26 | 2007-05-10 | Dainippon Sumitomo Pharma Co., Ltd | Novel condensed imidazole derivative |
| DE10355304A1 (de) | 2003-11-27 | 2005-06-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| EP1695969A4 (en) | 2003-12-11 | 2008-11-26 | Mitsubishi Tanabe Pharma Corp | ALPHA-AMINO-ACID DERIVATIVES AND THEIR USE AS MEDICINE |
| WO2005058849A1 (en) | 2003-12-15 | 2005-06-30 | Glenmark Pharmaceuticals Ltd. | New dipeptidyl peptidase in inhibitors; process for their preparation and compositions containing them |
| US7217711B2 (en) | 2003-12-17 | 2007-05-15 | Boehringer Ingelheim International Gmbh | Piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutical compositions |
| DE10360835A1 (de) | 2003-12-23 | 2005-07-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel |
| WO2005072530A1 (en) | 2004-01-16 | 2005-08-11 | Merck & Co., Inc. | Novel crystalline salts of a dipeptidyl peptidase-iv inhibitor |
| EP1559419A1 (en) | 2004-01-23 | 2005-08-03 | Fournier Laboratories Ireland Limited | Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention |
| KR20050076924A (ko) | 2004-01-26 | 2005-07-29 | 삼성전자주식회사 | 양방향 통신이 가능한 ｉ2ｃ 통신시스템 및 그 방법 |
| US7230002B2 (en) | 2004-02-03 | 2007-06-12 | Glenmark Pharmaceuticals Ltd. | Dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof |
| WO2005075426A1 (en) | 2004-02-03 | 2005-08-18 | Glenmark Pharmaceuticals Ltd. | Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| CA2555399A1 (en) | 2004-02-20 | 2005-09-01 | Novartis Ag | Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders |
| US20050203027A1 (en) | 2004-02-23 | 2005-09-15 | Trustees Of Tufts College | Inhibitors of dipeptidylpeptidase IV |
| DE102004009039A1 (de) | 2004-02-23 | 2005-09-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel |
| MXPA06009588A (es) | 2004-02-23 | 2007-03-30 | Tufts College | Lactamas como inhibidores peptidomimeticos restringidos mediante su configuracion. |
| WO2005086904A2 (en) | 2004-03-08 | 2005-09-22 | Amgen Inc. | Therapeutic modulation of ppar (gamma) activity |
| US20050215603A1 (en) | 2004-03-08 | 2005-09-29 | Irini Akritopoulou-Zanze | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
| US7348346B2 (en) | 2004-03-08 | 2008-03-25 | Abbott Laboratories | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
| US20070093492A1 (en) | 2004-03-09 | 2007-04-26 | Weir-Torn Jiaang | Pyrrolidine derivatives |
| CN1942186B (zh) | 2004-03-09 | 2010-10-06 | 国家卫生研究院 | 吡咯烷化合物 |
| US7393847B2 (en) | 2004-03-13 | 2008-07-01 | Boehringer Ingleheim International Gmbh | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions |
| MXPA06010571A (es) | 2004-03-15 | 2007-02-16 | Takeda Pharmaceutical | Inhibidores de dipeptidil peptidasa. |
| CN103435581B (zh) | 2004-03-16 | 2015-08-19 | 贝林格尔.英格海姆国际有限公司 | 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法 |
| US20050215882A1 (en) | 2004-03-23 | 2005-09-29 | The Regents Of The University Of Michigan | Noninvasive method to determine fat content of tissues using MRI |
| TW200538122A (en) | 2004-03-31 | 2005-12-01 | Bristol Myers Squibb Co | Process for preparing a dipeptidyl peptidase Ⅳ inhibitor and intermediates employed therein |
| US7179809B2 (en) | 2004-04-10 | 2007-02-20 | Boehringer Ingelheim International Gmbh | 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions |
| US8263121B2 (en) | 2004-04-14 | 2012-09-11 | Takeda Pharmaceutical Company Limited | Solid pharmaceutical preparation |
| US7741082B2 (en) | 2004-04-14 | 2010-06-22 | Bristol-Myers Squibb Company | Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor |
| TW200536827A (en) | 2004-05-04 | 2005-11-16 | Bristol Myers Squibb Co | Enzymatic ammonolysis process for the preparation of intermediates for DPP IV inhibitors |
| CA2564884A1 (en) | 2004-05-18 | 2005-12-08 | Merck & Co., Inc. | Cyclohexylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| US7687638B2 (en) | 2004-06-04 | 2010-03-30 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| DE102004030502A1 (de) | 2004-06-24 | 2006-01-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel |
| WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| MX2007000811A (es) | 2004-07-21 | 2007-04-02 | Kissei Pharmaceutical | Inhibidor de avance de enfermedad atribuida a acumulacion anormal de grasa en el higado. |
| EP1774310A4 (en) | 2004-07-23 | 2012-04-25 | Electric Power Res Inst | FLEXIBLE SENSOR FOR AN ELECTROMAGNETIC ACOUSTIC TRANSFORMER |
| US7054436B2 (en) | 2004-08-02 | 2006-05-30 | Sony Ericsson Mobile Communication, Ab | Communication terminals with a dual use speaker for sensing background noise and generating sound, and related methods and computer program products |
| US20060046978A1 (en) | 2004-08-31 | 2006-03-02 | Morphochem Ag | Novel compounds that inhibit dipeptidyl peptidase (DPP-IV) and neprilysin (NEP) and/or angiotensin converting enzyme (ACE) |
| DE102004043944A1 (de) | 2004-09-11 | 2006-03-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| DE102004044221A1 (de) | 2004-09-14 | 2006-03-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| US20060094693A1 (en) | 2004-09-21 | 2006-05-04 | Point Therapeutics, Inc. | Methods and compositions for treating glucose-associated conditions, metabolic syndrome, dyslipidemias and other conditions |
| AR051446A1 (es) | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
| AU2005293266B2 (en) | 2004-10-12 | 2011-09-29 | Glenmark Pharmaceuticals S.A. | Novel dipeptidyl peptidase IV inhibitors, pharmaceutical compositions containing them, and process for their preparation |
| AU2005295878A1 (en) | 2004-10-13 | 2006-04-27 | University Of Connecticut | Cannabinergic lipid ligands |
| US20060252670A1 (en) | 2004-10-14 | 2006-11-09 | Intercept Pharmaceuticals Inc. | Method of reducing drug-induced adverse side effects in a patient |
| EP1656934A1 (en) | 2004-11-12 | 2006-05-17 | Cognis IP Management GmbH | Use of physiologically active fatty acids for treating lipodystrophy |
| RU2401267C2 (ru) | 2004-11-30 | 2010-10-10 | Ф.Хоффманн-Ля Рош Аг | Замещенные производные бензохинолизина |
| ES2314743T3 (es) | 2004-12-16 | 2009-03-16 | Boehringer Ingelheim International Gmbh | Derivados de benceno sustituidos con glucopiranosilo, medicamentos que contienen a este tipo de compuestos, su uso y procedimiento para su fabricacion. |
| US7411093B2 (en) | 2004-12-20 | 2008-08-12 | Hoffman-La Roche Inc. | Aminocycloalkanes as DPP-IV inhibitors |
| KR100904829B1 (ko) | 2004-12-20 | 2009-06-25 | 에프. 호프만-라 로슈 아게 | 4-아미노피페리딘 유도체 |
| EP1828192B1 (en) | 2004-12-21 | 2014-12-03 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| KR20070113305A (ko) | 2005-03-22 | 2007-11-28 | 에프. 호프만-라 로슈 아게 | Ｄｐｐ-ｉｖ 저해제의 신규 염 및 동질이상체 |
| BRPI0608469A2 (pt) | 2005-04-22 | 2010-01-05 | Alantos Pharmaceuticals Holding Inc | inibidores de dipeptidil peptidase-iv |
| UA91546C2 (uk) | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
| US7723309B2 (en) | 2005-05-03 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
| US7644148B2 (en) | 2005-05-16 | 2010-01-05 | Hewlett-Packard Development Company, L.P. | Historical data based workload allocation |
| US7521557B2 (en) | 2005-05-20 | 2009-04-21 | Bristol-Myers Squibb Company | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods |
| US20060264433A1 (en) | 2005-05-23 | 2006-11-23 | Backes Bradley J | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
| US7825139B2 (en) | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| US20060270722A1 (en) | 2005-05-31 | 2006-11-30 | Thornberry Nancy A | Combination of a dipeptidyl peptidase-IV inhibitor and a dual PPAR agonist for the treatment of diabetes and obesity |
| BRPI0613447A2 (pt) | 2005-07-12 | 2016-11-16 | Daiichi Sankyo Co Ltd | composição farmacêutica, usos de um agonista de ppargama e de um agente biguanida, e, kit para evitar ocorrência de efeitos colaterais adversos devido à ação de um agente biguanida no tratamento do diabetes |
| EP1917001A2 (en) | 2005-08-11 | 2008-05-07 | F.Hoffmann-La Roche Ag | Pharmaceutical composition comprising a dpp-iv inhibitor |
| US7425633B2 (en) | 2005-08-26 | 2008-09-16 | National Health Research Institutes | Pyrrolidine compounds |
| EP1924571B1 (en) | 2005-08-30 | 2010-10-13 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
| WO2007027651A2 (en) | 2005-08-30 | 2007-03-08 | Abbott Laboratories | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv) |
| DE602006018961D1 (de) | 2005-09-08 | 2011-01-27 | Boehringer Ingelheim Pharma | KRISTALLINE FORMEN VON 1-CHLORO-4-(ß-D-GLUCOPYRANOS-1-YL)-2-(4-ETHYNYL-BENZYL)-BENZOL, ZUBEREITUNGSVERFAHREN DAFÜR UND DESSEN VERWENDUNG ZUR ARZNEIMITTELHERSTELLUNG |
| AR056195A1 (es) | 2005-09-15 | 2007-09-26 | Boehringer Ingelheim Int | Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos |
| AT502717A1 (de) | 2005-11-09 | 2007-05-15 | Omnica Gmbh | Pharmazeutische verwendung einer verbindung |
| WO2007054577A1 (en) | 2005-11-14 | 2007-05-18 | Probiodrug Ag | Cyclopropyl-fused pyrrolidine derivatives as dipeptidyl peptidase iv inhibitors |
| WO2007071576A1 (en) | 2005-12-21 | 2007-06-28 | F. Hoffmann-La Roche Ag | New salt and polymorph of dpp-iv inhibitor |
| UA91729C2 (ru) | 2005-12-22 | 2010-08-25 | Такеда Фармасьютикал Компани Лимитед | Твердая форма лекарственного препарата |
| EA200801773A1 (ru) | 2006-02-15 | 2009-02-27 | Бёрингер Ингельхайм Интернациональ Гмбх | Глюкопиранозилзамещенные производные бензонитрила, фармацевтические композиции, содержащие такие соединения, их применение и способ их получения |
| US20070239536A1 (en) | 2006-04-05 | 2007-10-11 | General Electric Company | System and method for scheduling audience deficiency units and makegoods |
| PE20080697A1 (es) | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
| PT2032134E (pt) | 2006-05-09 | 2015-10-07 | Genzyme Corp | Métodos de tratamento da doença do fígado gorduroso |
| RU2452469C2 (ru) | 2006-07-21 | 2012-06-10 | Новартис Аг | Составы бензимидазолилпиридилэфиров |
| US8283326B2 (en) | 2006-10-27 | 2012-10-09 | Boehringer Ingelheim International Gmbh | Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
| TW200829258A (en) | 2006-11-06 | 2008-07-16 | Boehringer Ingelheim Int | Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture |
| TWI448291B (zh) | 2006-11-09 | 2014-08-11 | Boehringer Ingelheim Int | 使用ｓｇｌｔ-２抑制劑之組合療法及彼等之醫藥組合物 |
| WO2008067378A2 (en) | 2006-11-28 | 2008-06-05 | Auspex Pharmaceuticals, Inc. | Preparation and utility of substituted phenyltetrazoles |
| US20070172525A1 (en) | 2007-03-15 | 2007-07-26 | Ramesh Sesha | Anti-diabetic combinations |
| US20090074862A1 (en) | 2007-04-13 | 2009-03-19 | Luigi Schioppi | Low-dose doxepin formulations and methods of making and using the same |
| CA2693628A1 (en) | 2007-07-11 | 2009-01-15 | Cardoz Ab | New combination for use in the treatment of imflammatory disorders |
| WO2009015179A1 (en) * | 2007-07-23 | 2009-01-29 | Syndax Pharmaceuticals, Inc. | Novel compounds and methods of using them |
| CN101361968B (zh) | 2007-08-06 | 2011-08-03 | 健能隆医药技术（上海）有限公司 | 白介素-22在治疗脂肪肝中的应用 |
| EP2242747A1 (de) | 2008-02-07 | 2010-10-27 | Sanofi-Aventis | Substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung |
| WO2009097996A1 (de) | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Verwendung von substituierten phenylimidazolidinen zur herstellung von arzneimitteln zur behandlung des metabolischen syndroms |
| US20130245024A1 (en) | 2008-03-06 | 2013-09-19 | Dennis Lanfear | Combination of PPARy Agonist and a Dipeptidyl Peptidase-Inhibitor for the Treatment of Diabetes and Obesity |
| JPWO2009151116A1 (ja) * | 2008-06-13 | 2011-11-17 | 持田製薬株式会社 | 非アルコール性脂肪肝炎の予防／改善・治療薬 |
| US20100087481A1 (en) | 2008-10-03 | 2010-04-08 | Lee Kathleen M | Oral pharmaceutical formulations for antidiabetic compounds |
| JP2010265216A (ja) | 2009-05-14 | 2010-11-25 | Takeda Chem Ind Ltd | 複素環化合物 |
| US9028879B2 (en) | 2009-07-01 | 2015-05-12 | Jds Therapeutics, Llc | Chromium complexes as enhancers of brain glucose transporters |
| WO2011017488A2 (en) * | 2009-08-05 | 2011-02-10 | Intekrin Therapeutics, Inc. | Combination of a selective ppar-gamma modulator and an incretin for the treatment of diabetes and obesity |
| WO2012040082A2 (en) | 2010-09-21 | 2012-03-29 | Intekrin Therapeutics, Inc. | Antidiabetic solid pharmaceutical compositions |
| US8477001B2 (en) | 2010-09-21 | 2013-07-02 | Remy Technologies Llc | Starter solenoid with rectangular coil winding |
| CA2811297C (en) | 2010-09-26 | 2016-10-25 | Donald O'keefe | Method of recombinant macromolecular production |
| US9072732B2 (en) | 2010-11-22 | 2015-07-07 | The Regents Of The University Of California | Indication for use of niacin (nicotinic acid) for treatment and reversal of fatty liver disease |
| TWI435605B (zh) | 2010-11-29 | 2014-04-21 | Realtek Semiconductor Corp | 透過高解析度多媒體介面來進行網路連線之網路裝置及網路連線方法 |
| ES2389547B1 (es) | 2010-12-07 | 2013-08-08 | Consejo Superior De Investigaciones Científicas (Csic) | Bifidobacterium cect 7765 y su uso en la prevención y/o tratamiento del sobrepeso, la obesidad y patologías asociadas. |
| US8865641B2 (en) | 2011-06-16 | 2014-10-21 | The Feinstein Institute For Medical Research | Methods of treatment of fatty liver disease by pharmacological activation of cholinergic pathways |
| US9044433B2 (en) | 2011-10-06 | 2015-06-02 | Vanderbilt University | Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome |
| WO2013071077A1 (en) | 2011-11-09 | 2013-05-16 | Cornell University | The use of pan-ppar agonists for prevention and treatment of huntington's disease and tauopathies |
| JP5525511B2 (ja) * | 2011-12-27 | 2014-06-18 | 農業生産法人株式会社 熱帯資源植物研究所 | 非アルコール性脂肪性肝疾患および／または非アルコール性脂肪肝炎の治療薬 |
| KR101186500B1 (ko) | 2012-01-31 | 2012-09-27 | 연세대학교 산학협력단 | 신규한 피페린 유도체 및 그의 용도 |
| WO2013134241A1 (en) | 2012-03-05 | 2013-09-12 | The University Of Montana | Novel aspartylamide inhibitors of excitatory amino acid transporters |
| EA201590726A1 (ru) | 2012-10-12 | 2015-10-30 | Тева Фармасьютикал Индастриз Лтд. | Лахинимод для уменьшения таламического поражения при рассеянном склерозе |
| BR112015018048A2 (pt) | 2013-01-30 | 2020-01-28 | Intekrin Therapeutics Inc | agonistas de ppary para tratamento de esclerose múltipla |
| BR122019026188B1 (pt) | 2013-03-15 | 2024-01-02 | Somalogic Operating Co., Inc | Métodos para determinar se um indivíduo com esteatose não alcoólica tem esteato-hepatite não alcoólica e para monitorar um indivíduo com esteatose não alcoólica para o desenvolvimento de nash |
| US10441560B2 (en) | 2013-03-15 | 2019-10-15 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| TWI696462B (zh) * | 2013-07-10 | 2020-06-21 | 日商興和股份有限公司 | 非酒精性脂肪性肝疾病治療劑 |
| AU2014364447A1 (en) | 2013-12-20 | 2016-08-04 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod to delay Huntington's disease progression |
| SG11201607075TA (en) | 2014-02-27 | 2016-09-29 | Nusirt Sciences Inc | Compositions and methods for the reduction or prevention of hepatic steatosis |
| RU2709205C2 (ru) | 2014-10-10 | 2019-12-17 | Прометик Фарма Смт Лимитед | Замещенные ароматические соединения и фармацевтические композиции для предотвращения и лечения остеопороза |
| CN104299589B (zh) | 2014-10-29 | 2016-05-25 | 京东方科技集团股份有限公司 | 移位寄存器单元电路、移位寄存器、驱动方法及显示装置 |
| KR20160061492A (ko) | 2014-11-21 | 2016-06-01 | 삼성디스플레이 주식회사 | 휴대용 먼지 센서 및 이를 이용한 휴대전화 |
| WO2016144862A1 (en) | 2015-03-09 | 2016-09-15 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
| PE20180034A1 (es) | 2015-04-07 | 2018-01-09 | Intercept Pharmaceuticals Inc | Composiciones farmaceuticas para terapias combinadas |
| US10857209B2 (en) | 2016-02-12 | 2020-12-08 | Indiana University Research And Technology Corporation | Lysosomal acid lipase and PPAR gamma ligands as immune therapies for cancer treatment |
| PL3468604T3 (pl) | 2016-06-08 | 2021-07-12 | Support-Venture Gmbh | Kombinacje farmaceutyczne do leczenia nowotworu złośliwego |
| EP3500269A4 (en) | 2016-08-18 | 2020-04-15 | Intekrin Therapeutics, Inc. | PPARY AGONIST FOR THE TREATMENT OF BONE DISORDERS |
| EA201990512A1 (ru) | 2016-08-18 | 2019-08-30 | Интекрин Терапьютикс, Инк. | АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ КЛЕТОК КРОВИ |
| SG10202102198RA (en) | 2016-09-13 | 2021-04-29 | Intekrin Therapeutics Inc | Treatment of multiple sclerosis with chs-131 |
| US11350844B2 (en) | 2016-11-23 | 2022-06-07 | Mayo Foundation For Medical Education And Research | System and method for generating nonalcoholic fatty liver disease activity score (NAS) using magnetic resonance elastography |
| ES3026786T3 (en) | 2017-01-11 | 2025-06-12 | Kowa Co | Pemafibrate in combination with a sglt2 inhibitor for the prophylactic or therapeutic treatment of liver diseases nonalcoholic fatty liver disease |
| CN110461330A (zh) | 2017-01-18 | 2019-11-15 | 科赫罗斯生物科学股份有限公司 | 用于治疗亨廷顿氏病的PPARγ激动剂 |
| KR20200036808A (ko) | 2017-04-03 | 2020-04-07 | 코히러스 바이오사이언시스, 인크. | 진행성 핵상 마비 치료를 위한 PPARγ 작용제 |
| CA3058542A1 (en) | 2017-04-18 | 2018-10-25 | Genfit | Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor |
| EA201992364A1 (ru) | 2018-04-02 | 2020-03-23 | Кохерус Байосайенсис Инк. | АГОНИСТ PPARγ ДЛЯ ЛЕЧЕНИЯ ПРОГРЕССИРУЮЩЕГО НАДЪЯДЕРНОГО ПАРАЛИЧА |
| WO2020142365A1 (en) | 2018-12-31 | 2020-07-09 | Christos Mantzoros | Compositions and methods to treat non-alcoholic fatty liver diseases (nafld) |
| EP3946336A1 (en) | 2019-04-02 | 2022-02-09 | Coherus Biosciences, Inc. | Compositions and methods to treat non-alcoholic fatty liver diseases (nafld) |
| EP3946335A1 (en) | 2019-04-04 | 2022-02-09 | Coherus Biosciences, Inc. | Compositions and methods to treat non-alcoholic fatty liver diseases (nafld) |
| US20240066020A1 (en) | 2019-10-15 | 2024-02-29 | Coherus Biosciences, Inc. | Compositions and methods to treat non-alcoholic fatty liver diseases (nafld) |
-
2016
- 2016-03-07 WO PCT/US2016/021162 patent/WO2016144862A1/en not_active Ceased
- 2016-03-07 BR BR112017019170-9A patent/BR112017019170A2/pt not_active Application Discontinuation
- 2016-03-07 CA CA2979033A patent/CA2979033A1/en active Pending
- 2016-03-07 CN CN201680024598.5A patent/CN107683135A/zh active Pending
- 2016-03-07 MA MA042450A patent/MA42450A/fr unknown
- 2016-03-07 SG SG10202103552XA patent/SG10202103552XA/en unknown
- 2016-03-07 EP EP16762290.1A patent/EP3267994A4/en not_active Withdrawn
- 2016-03-07 HK HK18109209.8A patent/HK1249847A1/zh unknown
- 2016-03-07 MX MX2017011586A patent/MX386778B/es unknown
- 2016-03-07 EA EA201791982A patent/EA201791982A1/ru unknown
- 2016-03-07 KR KR1020177027320A patent/KR20180006881A/ko not_active Ceased
- 2016-03-07 JP JP2017566609A patent/JP2018507914A/ja active Pending
- 2016-03-07 AU AU2016229982A patent/AU2016229982B2/en not_active Ceased
- 2016-03-07 US US15/062,331 patent/US10555929B2/en not_active Expired - Fee Related
- 2016-03-07 SG SG11201707276PA patent/SG11201707276PA/en unknown
- 2016-03-07 KR KR1020227016427A patent/KR20220070057A/ko not_active Ceased
- 2016-03-09 TW TW105107187A patent/TWI769976B/zh not_active IP Right Cessation
-
2017
- 2017-09-03 IL IL254282A patent/IL254282A0/en unknown
- 2017-09-08 MX MX2021011949A patent/MX2021011949A/es unknown
-
2020
- 2020-01-16 US US16/744,433 patent/US10772865B2/en not_active Expired - Fee Related
- 2020-06-25 US US16/911,721 patent/US11400072B2/en active Active
- 2020-09-14 AU AU2020233626A patent/AU2020233626B2/en not_active Ceased
- 2020-12-17 JP JP2020209008A patent/JP2021063088A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20160263098A1 (en) | 2016-09-15 |
| CN107683135A (zh) | 2018-02-09 |
| US10772865B2 (en) | 2020-09-15 |
| US20200147036A1 (en) | 2020-05-14 |
| US11400072B2 (en) | 2022-08-02 |
| KR20220070057A (ko) | 2022-05-27 |
| SG11201707276PA (en) | 2017-10-30 |
| IL254282A0 (en) | 2017-10-31 |
| CA2979033A1 (en) | 2016-09-15 |
| EP3267994A1 (en) | 2018-01-17 |
| JP2021063088A (ja) | 2021-04-22 |
| TWI769976B (zh) | 2022-07-11 |
| EP3267994A4 (en) | 2018-10-31 |
| MX386778B (es) | 2025-03-19 |
| BR112017019170A2 (pt) | 2018-07-10 |
| US20200383945A1 (en) | 2020-12-10 |
| AU2016229982B2 (en) | 2020-06-18 |
| MX2021011949A (es) | 2021-11-03 |
| EA201791982A1 (ru) | 2020-02-17 |
| SG10202103552XA (en) | 2021-05-28 |
| HK1249847A1 (zh) | 2018-11-16 |
| JP2018507914A (ja) | 2018-03-22 |
| TW201639571A (zh) | 2016-11-16 |
| MX2017011586A (es) | 2017-10-26 |
| AU2020233626A1 (en) | 2020-10-08 |
| US10555929B2 (en) | 2020-02-11 |
| WO2016144862A1 (en) | 2016-09-15 |
| MA42450A (fr) | 2018-05-23 |
| AU2020233626B2 (en) | 2022-06-02 |
| AU2016229982A1 (en) | 2017-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020233626B2 (en) | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy | |
| RU2743075C2 (ru) | Способы применения агонистов fxr | |
| US9757404B2 (en) | Combination comprising an omega-3 fatty acid composition and an SGLT2 inhibitor | |
| CN110876751A (zh) | 曲美替尼在制备预防和/或治疗非酒精性肝炎和/或非酒精性脂肪性肝病中的应用 | |
| JP2019530696A (ja) | 線維性、硬変性の疾患もしくは障害を治療または予防するためのｆｘｒアゴニストを含む組合せ組成物 | |
| Zhou et al. | Keverprazan, a novel potassium-competitive acid blocker: Single ascending dose safety, tolerability, pharmacokinetics, pharmacodynamics and food effect in healthy subjects | |
| CN114080234A (zh) | 包含fxr激动剂的治疗 | |
| CN109689050A (zh) | Fxr激动剂的新方案 | |
| CN111093705A (zh) | 包含fxr激动剂的组合 | |
| US20250177353A1 (en) | Methods of treating mitochondria-related disorders | |
| US20250134864A1 (en) | Methods of weight loss and preserving skeletal muscle mass | |
| WO2019099509A1 (en) | Use of a p2x7 receptor antagonist to treat an inflammatory disease or disorder | |
| Ku et al. | Carotid intimal-medial thickness is not increased in women with previous gestational diabetes mellitus | |
| EA042686B1 (ru) | Способ лечения неалкогольного стеатогепатита | |
| Ahmad et al. | Phase 1 study of EDP‐305, a novel once‐daily oral farsenoid× receptor agonist, in healthy subjects and those with presumptive nonalcoholic fatty liver disease | |
| US20250134865A1 (en) | Methods of weight loss in a subject with elevated hba1c | |
| JP2025526746A (ja) | 門脈圧亢進症を伴う肝硬変の治療のための併用療法 | |
| HK40080642A (en) | Therapeutic agent for fatty liver disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20170926 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20210305 Comment text: Request for Examination of Application |
|
| PA0302 | Request for accelerated examination |
Patent event date: 20210305 Patent event code: PA03022R01D Comment text: Request for Accelerated Examination |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20210712 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20220215 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20210712 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20220516 |